EGFR、neu、PCNA在卵巢浆液性癌中表达与临床、病理、预后的关系
Expression of EGFR. neu and PCNA in 70 Patients with ovarian Surous Cystadenocarcinoma and Their Clinical Significance
-
摘要: 本实验对70例卵巢浆液癌、10例交界性癌、20例卵巢浆液瘤中EGFR（表皮生长因子受体）、neu癌基因、PCNA（增殖细胞核抗原）表达进行研究，观察其在卵巢癌、交界性肿瘤、良性瘤的表达率，并采用半定量的ABC免疫组化方法研究不同强度表达与病理分化、临床分期、预后的关系，得到初步结果。EGFR在浆液癌表达58.5%,交界瘤50%,浆液瘤5%,其表达率与预后呈负相关，与病理分化、临床分期无明显相关性。neu在卵巢浆液癌中表达45.7%,交界瘤20%,浆液瘤0,其阳性表达率及表达强度与预后和病理分化有关。PCNA在浆液癌中表达47%,交界瘤中30%,良性瘤10%,其表达强度与预后和病理分化有关。本实验表明EGFR、neu、PCNA与卵巢浆液癌预后有相关性，neu、PCNA与病理分化也有一定相关性。可能成为判断病理分化、临床预后的指标。Abstract: The expression of EGFR、neu and PCNA in 70 Patients with ovarian surous cystadenocarcinoma was observed with immunohistochemical technique in this study.The relationship between the expression and clinical feature including various pathological grades,clinical stages and prognosis was studied.The results showed that in these 70 patients EGFR was positive in 41(58.5%),neu was posttive in 32(45.7%),PCNA was positive in 33(47%).EGFR、 neu and PCNA expression was significantly correlated to the pathological grade and clinical prognosis.
下载:
